BHCM
CATX icon

Brevan Howard Capital Management’s Perspective Therapeutics CATX Stock Holding History

Brevan Howard Capital Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.8K Buy
+13,726
New +$51.9K ﹤0.01% 2018
2024
Q2 		– Sell
-3,899
Closed -$46.4K – 1093
2024
Q1 		$46.4K Buy
+3,899
New +$33.2K ﹤0.01% 941

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Brevan Howard Capital Management's CATX Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 13,726 shares worth $46.8K. The stake represents ﹤0.01% of the portfolio and ranks #2018 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in CATX as recently as Q1 2024.

Brevan Howard Capital Management first reported a position in CATX in Q1 2024 and has held it in 2 quarters since. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Brevan Howard Capital Management held 13,726 shares of Perspective Therapeutics worth $46.8K as of Q2 2026.
  • Perspective Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #2018 holding.
  • Brevan Howard Capital Management first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.